Compare THQ & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THQ | FTH |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 779.0M | 860.0M |
| IPO Year | N/A | 2021 |
| Metric | THQ | FTH |
|---|---|---|
| Price | $19.49 | $28.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 196.3K | ★ 314.5K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.49 | $17.50 |
| 52 Week High | $20.39 | $37.90 |
| Indicator | THQ | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 57.42 |
| Support Level | $18.90 | $22.69 |
| Resistance Level | $20.14 | $31.61 |
| Average True Range (ATR) | 0.22 | 2.82 |
| MACD | 0.05 | -0.37 |
| Stochastic Oscillator | 98.02 | 71.16 |
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.